BioXcel Therapeutics (BTAI) Gross Margin (2022 - 2025)
Historic Gross Margin for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 88.78%.
- BioXcel Therapeutics' Gross Margin rose 5355000.0% to 88.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.19%, marking a year-over-year decrease of 391800.0%. This contributed to the annual value of 5.43% for FY2024, which is 32700.0% down from last year.
- Latest data reveals that BioXcel Therapeutics reported Gross Margin of 88.78% as of Q3 2025, which was up 5355000.0% from 10.83% recorded in Q2 2025.
- In the past 5 years, BioXcel Therapeutics' Gross Margin ranged from a high of 96.22% in Q4 2022 and a low of 446.73% during Q3 2024
- Moreover, its 4-year median value for Gross Margin was 88.78% (2025), whereas its average is 2.77%.
- In the last 5 years, BioXcel Therapeutics' Gross Margin plummeted by -3965800bps in 2024 and then soared by 5355000bps in 2025.
- Quarter analysis of 4 years shows BioXcel Therapeutics' Gross Margin stood at 96.22% in 2022, then plummeted by -193bps to 89.89% in 2023, then plummeted by -42bps to 127.32% in 2024, then skyrocketed by 170bps to 88.78% in 2025.
- Its Gross Margin stands at 88.78% for Q3 2025, versus 10.83% for Q2 2025 and 91.67% for Q1 2025.